Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

NCT07509034 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

NIH

Sponsor class

Conditions

Extensive-Stage Small Cell Lung Cancer
Extrapulmonary Neuroendocrine Carcinoma
Recurrent or Refractory
Solid Tumors

Interventions

DRUG: Autologous B7-H3 CAR T
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)